GTEx Lung 20-29 vs 40-49 Up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GTEx Lung 20-29 vs 40-49 Up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GTEx Lung 20-29 vs 40-49 Up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GTEx Lung 20-29 vs 40-49 Up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GTEx Lung 20-29 vs 40-49 Up.

Results found

Linked to

 

Label

Description

 

Gene

protein kinase Y-linked (pseudogene)

Gene

taxilin gamma Y-linked (pseudogene)

Gene

MT-ND1 pseudogene 23

Gene

inositol polyphosphate multikinase pseudogene

Gene

MIR205 host gene

Gene

MAP3K2 divergent transcript

Gene

DPP10 antisense RNA 1

Gene

NR4A1 antisense RNA

Gene

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase...

Gene

long intergenic non-protein coding RNA 2532

  • Gene

    protein kinase Y-linked (pseudogene)


  • Gene

    taxilin gamma Y-linked (pseudogene)


  • Gene

    MT-ND1 pseudogene 23


  • Gene

    inositol polyphosphate multikinase pseudogene



  • Gene

    MAP3K2 divergent transcript


  • Gene

    DPP10 antisense RNA 1


  • Gene

    NR4A1 antisense RNA


  • Gene

    methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase...


  • Gene

    long intergenic non-protein coding RNA 2532

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.